Islatravir news

All news on Islatravir (also known as MK-8591): plants, production capacities, investments and involved companies.

25 February 2026

Merck Presents Phase 3 Trial Results for HIV-1 Treatment DOR/ISL at CROI 2026

DOR/ISL shows non-inferiority and similar safety to BIC/FTC/TAF in HIV-1 treatment-naïve adults and maintains suppression in those switching from other therapies.
19 November 2025

Merck Reports Positive Phase 3 Trial Results for HIV-1 Treatment DOR/ISL

DOR/ISL shows non-inferiority to BIC/FTC/TAF in HIV-1 treatment-naïve adults, meeting efficacy and safety goals. Detailed findings to be presented at a future scientific congress.
15 October 2025

Merck Reports Phase 3 Trial Data on Doravirine-Islatravir Regimen

Phase 3 trials show minimal weight, body composition, and lipid changes with the DOR/ISL regimen in HIV-1 patients, maintaining viral suppression without resistance.

Who will be producing Islatravir in the future?

Find out with chemXplore Analytics